Want to see HK:1530 full AI Analyst Report?
1530 Stock Chart & Stats
HK$17.14
HK$0.34(1.98%)
At close: 4:00 PM EDT
HK$17.14
HK$0.34(1.98%)
Day’s Range― - ―
52-Week RangeHK$14.81 - HK$36.80
Previous CloseN/A
Volume13.82M
Average Volume (3M)31.12M
Market Cap
HK$45.26B
Enterprise ValueHK$28.64K
Total Cash (Recent Filing)HK$19.73B
Total Debt (Recent Filing)HK$2.62B
Price to Earnings (P/E)4.6
Beta0.85
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.4%
Share Statistics
EPS (TTM)3.44
Shares Outstanding2,538,239,500
10 Day Avg. Volume32,899,411
30 Day Avg. Volume31,124,824
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.53Price Target Upside72.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$9.73B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability GrowthRevenue rose about 90% in 2025 while gross, operating, and net margins reached approximately 92%, 60%, and 48%. This operating scale-up could strengthen earnings capacity and fund continued commercialization if the expanded performance is maintained.
Strong Cash GenerationOperating cash flow of ~9.7B and free cash flow of ~9.1B in 2025, with FCF at ~0.94x net income, indicate strong earnings quality. This internally generated liquidity can support investment and reduce reliance on external financing.
Conservative Balance SheetDebt-to-equity fell to ~0.10 in 2025 from ~0.23 in 2024 and ~0.35 in 2022–2023, while assets and equity expanded. Lower leverage improves resilience and preserves flexibility to fund products, operations, or growth initiatives.
Bears Say
Earnings Durability RiskThe 2025 improvement was unusually large: revenue rose ~90% and net margin reached ~48%, after materially less consistent growth and margins in 2020–2024. Reversion would make current earnings and cash capacity less dependable over the medium term.
Historical Cash Conversion VolatilityOperating cash flow trailed net income in 2023–2024, while free cash flow to net income was only ~0.66–0.70x. Although 2025 improved sharply, this history signals working-capital or timing pressures that could recur.
Limited Forward VisibilityManagement provided no guidance, highlights, or lowlights in the available earnings-call analysis. That limits visibility into whether 2025's exceptional growth, margins, and cash generation can continue, making forward planning and earnings durability harder to assess.
3SBio News
1530 FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was HK$14.81 and its highest was HK$36.80 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is HK$45.26B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Mar 30, 2027 which is in 218 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Aug 20, 2026. The company reported HK$0.513 earnings per share for the quarter, missing the consensus estimate of HK$0.747 by -HK$0.233.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 1.4%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3SBio have?
3SBio has 2,538,239,500 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of HK$0.513 in its last earnings report, missing expectations of HK$0.747. Following the earnings report the stock price went down -1.138%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in HK:1530
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$29.53 (72.31% Upside)
HK$29.53 (72.31% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
456.34%
12-Months-Change
Fundamentals
Return on Equity
1.40%
Trailing 12-Months
Asset Growth
56.38%
Trailing 12-Months
Company Description
3SBio
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
1530 Stock 12 Month Forecast
Average Price Target
HK$29.53
▲(72.31% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―